BASi offers GLP and non-GLP ligand binding assays (LBA) for macromolecular drug therapeutics, immunogenicity screening or biomarkers in
biological matrices.
Our large molecule program is built upon our strong foundation of experienced scientists and project managers in
conjunction with the latest equipment and technology for immunoassay detection and quantification for PK/TK studies. With
the increasing pressure to provide early go/no-go decisions, BASi is well equipped to handle studies involving biomarkers
as primary or secondary endpoints for indication of efficacy, safety, disease state or mechanism of action.
Large Molecule Services include:
- Macromolecule PK/TK (hybridization and immunoassays)
- Immunogenicity assays (anti-drug antibody assays)
- Biomarker services for drug development (i.e. PD, safety assessment, mechanism of action)
- EIA- or ELISA-based applications
- Enzyme kinetic assays
- Method development, validation and sample analysis of proteins, peptides and oligonucleotides
|
 |
